CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Revenues	$ 1,663,496	$ 1,500,673	$ 4,783,003	$ 4,289,780
Expenses:
Research and development	556,972	529,749	1,584,847	1,547,159
Selling, general, and administrative	369,232	306,766	1,064,886	910,520
Total expenses	1,036,573	940,747	2,966,661	2,749,000
Income from operations	626,923	559,926	1,816,342	1,540,780
Other income (expense):
Other income (expense), net	16,432	11,861	81,842	2,048
Interest expense	(7,494)	(6,182)	(20,851)	(19,084)
Total other income (expense)	8,938	5,679	60,991	(17,036)
Income before income taxes	635,861	565,605	1,877,333	1,523,744
Income tax expense	(41,206)	(177,288)	(253,286)	(498,752)
Net income	$ 594,655	$ 388,317	$ 1,624,047	$ 1,024,992
Net income per share - basic (in dollars per share)	$ 5.50	$ 3.64	$ 15.06	$ 9.66
Net income per share - diluted (in dollars per share)	$ 5.17	$ 3.32	$ 14.14	$ 8.84
Weighted average shares outstanding - basic (in shares)	108,033	106,706	107,828	106,108
Weighted average shares - diluted (in shares)	115,088	117,028	114,843	115,994
Statements of Comprehensive Income
Net income	$ 594,655	$ 388,317	$ 1,624,047	$ 1,024,992
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on marketable securities	752	21,485	(6,954)	36,645
Unrealized gain on cash flow hedges	341	2	2,388	30
Comprehensive income	595,748	409,804	1,619,481	1,061,667
Product
Revenues:
Revenues	1,025,488	957,367	3,009,779	2,739,745
Expenses:
Cost of goods sold	30,817	46,388	136,010	149,774
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	79,552	57,844	180,918	141,547
Sanofi | Product and service, other
Revenues:
Revenues	256,265	245,175	683,508	677,670
Bayer | Product and service, other
Revenues:
Revenues	264,373	236,625	775,164	640,919
Other | Product and service, other
Revenues:
Revenues	$ 117,370	$ 61,506	$ 314,552	$ 231,446